Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Help seeking: Why isn’t it as simple as it might sound? August 10, 2022 EMA Recommends Extension of Indications for Blinatumomab June 9, 2021 Beauty, Healing and Space January 27, 2021 Nature’s Bounty: Revitalizing the Discovery of New Cancer Drugs from Natural... March 22, 2019 Load more HOT NEWS Why people and culture matter in research Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... Hugh Jackman Stops His Show To Bring Woman With Breast Cancer... Majority of Patients With Cancer Are Willing To Be Vaccinated Against...
